To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Co…

Phase 2 StudyBMS-986504MTAP-deleted Pancreatic Cancer

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07283705

Phase 2

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.

Phase 2 StudyBlinatumomabAcute Lymphoblastic Leukemia

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07192237

Phase 2

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.

Phase 2 StudyMCLBTKi+2 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07257055